Drug Trial Radar · NCT04233879
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
599
Actual
Start
Feb 28, 2020
Primary completion
Nov 17, 2022
Study completion Jan 29, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL \[also known as MK-8591A\]) in treatment-naïve participants living with human immunodeficiency virus type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.
Conditions
- HIV-1 Infection
Interventions
DOR/ISLDrug
100 mg DOR/0.75 mg ISL FDC single tablet taken once daily by mouth.
BIC/FTC/TAFDrug
BIC/FTC/TAF 50/200/25 mg FDC single tablet taken once daily by mouth.
Placebo to BIC/FTC/TAFDrug
Placebo single tablet matched to BIC/FTC/TAF taken by mouth.
Placebo to DOR/ISLDrug
Placebo single tablet matched to DOR/ISL taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48Time frame: Week 48
- Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48Time frame: Up to approximately 48 weeks
- Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48Time frame: Up to approximately 48 weeks
Locations
95 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham 1917 Research Clinic ( Site 5610)
Birmingham, Alabama
Pueblo Family Physicians ( Site 5606)
Phoenix, Arizona
Ruane Clinical Research Group, Inc. ( Site 5624)
Los Angeles, California
Midway Immunology and Research ( Site 5622)
Ft. Pierce, Florida
The Kinder Medical Group ( Site 5615)
Miami, Florida
Floridian Clinical Research, LLC ( Site 5625)
Miami Lakes, Florida
Orlando Immunology Center ( Site 5613)
Orlando, Florida
CAN Community Health ( Site 5627)
Sarasota, Florida
Triple O Research Institute, P.A. ( Site 5621)
West Palm Beach, Florida
Columbus Regional Research Institute ( Site 5616)
Columbus, Georgia
Infectious Disease Specialists Of Atlanta PC ( Site 5608)
Decatur, Georgia
Hennepin Healthcare-Hennepin Healthcare-ID ( Site 5633)
Minneapolis, Minnesota
Kansas City CARE Clinic ( Site 5607)
Kansas City, Missouri
University of Pennsylvania ( Site 5630)
Philadelphia, Pennsylvania
Saint Hope Foundation, Inc. ( Site 5629)
Bellaire, Texas
North Texas ID Consultants, PA ( Site 5604)
Dallas, Texas
Texas Centers for Infectious Disease Associates P.A. ( Site 5619)
Fort Worth, Texas
Instituto Oulton ( Site 5804)
Córdoba, Argentina
Helios Salud S.A. ( Site 5802)
Buenos Aires, Buenos Aires F.D., Argentina
IDEAA Foundation ( Site 5807)
Buenos Aires, Buenos Aires F.D., Argentina
Fundación Huesped ( Site 5801)
C.a.b.a, Buenos Aires F.D., Argentina
Instituto CAICI ( Site 5803)
Rosario, Santa Fe Province, Argentina
Hamilton Health Sciences- Urgent Care Centre-SIS Clinic ( Site 5703)
Hamilton, Ontario, Canada
Toronto General Hospital - University Health Network ( Site 5705)
Toronto, Ontario, Canada
Clinique Medicale L Actuel ( Site 5714)
Montreal, Quebec, Canada
McGill University Health Center - Research Institute-CVIS Clinical Research Unit ( Site 5702)
Montreal, Quebec, Canada
Hospital Dr. Hernan Henriquez Aravena ( Site 5905)
Temuco, Araucania, Chile
Clinica Universidad Catolica del Maule ( Site 5909)
Talca, Maule Region, Chile
Clinica Arauco Salud ( Site 5900)
Santiago, Region M. de Santiago, Chile
Hospital Clinico de la Universidad Catolica ( Site 5903)
Santiago, Region M. de Santiago, Chile
Fundacion Arriaran ( Site 5901)
Santiago, Region M. de Santiago, Chile
Centro Cardiovascular Cardiosur ( Site 5907)
Santiago, Region M. de Santiago, Chile
Hospital Universitario San Ignacio ( Site 6005)
Bogotá, Bogota D.C., Colombia
Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 6006)
Bogotá, Bogota D.C., Colombia
Fundacion Valle del Lili ( Site 6001)
Cali, Valle del Cauca Department, Colombia
A.P.H. Paris, Hopital Saint Louis ( Site 6114)
Paris, France
Hopital Saint-Antoine ( Site 6113)
Paris, France
Hopital Pitie Salpetriere ( Site 6111)
Paris, France
A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 6124)
Paris, Ain, France
Hopital de la Croix-Rousse ( Site 6127)
Lyon, Auvergne-Rhône-Alpes, France
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.